196 related articles for article (PubMed ID: 23829374)
1. Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target.
Lee CR; Lee JH; Jeong BC; Lee SH
Curr Pharm Des; 2013; 19(36):6534-50. PubMed ID: 23829374
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
3. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
4. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
5. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
6. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
Erwin AL
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
9. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
10. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
[TBL] [Abstract][Full Text] [Related]
13. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
14. Structure guided design of an antibacterial peptide that targets UDP-N-acetylglucosamine acyltransferase.
Dangkulwanich M; Raetz CRH; Williams AH
Sci Rep; 2019 Mar; 9(1):3947. PubMed ID: 30850651
[TBL] [Abstract][Full Text] [Related]
15. Exploring the UDP pocket of LpxC through amino acid analogs.
Hale MR; Hill P; Lahiri S; Miller MD; Ross P; Alm R; Gao N; Kutschke A; Johnstone M; Prince B; Thresher J; Yang W
Bioorg Med Chem Lett; 2013 Apr; 23(8):2362-7. PubMed ID: 23499237
[TBL] [Abstract][Full Text] [Related]
16. A method to assay inhibitors of lipopolysaccharide synthesis.
Hernick M; Fierke CA
Methods Mol Med; 2008; 142():143-54. PubMed ID: 18437312
[TBL] [Abstract][Full Text] [Related]
17. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
[TBL] [Abstract][Full Text] [Related]
18. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.
Barb AW; Zhou P
Curr Pharm Biotechnol; 2008 Feb; 9(1):9-15. PubMed ID: 18289052
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting antibacterial peptide inhibitor of early lipid A biosynthesis.
Jenkins RJ; Dotson GD
ACS Chem Biol; 2012 Jul; 7(7):1170-7. PubMed ID: 22530734
[TBL] [Abstract][Full Text] [Related]
20. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
Supuran CT; Carta F; Scozzafava A
Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
